US006884773B1

(12) **United States Patent**
Stamler et al.

(10) **Patent No.: US 6,884,773 B1**
(45) **Date of Patent: *Apr. 26, 2005**

(54) **MODIFIED HEMOGLOBINS, INCLUDING NITROSYLHEMOGLOBINS, AND USES THEREOF**

(75) Inventors: **Jonathan S. Stamler**, Chapel Hill, NC (US); **Andrew J. Gow**, Doylestown, PA (US)

(73) Assignee: **Duke University**, Durham, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 514 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **08/796,164**

(22) Filed: **Feb. 6, 1997**

Related U.S. Application Data

(63) Continuation-in-part of application No. PCT/US96/14659, filed on Sep. 13, 1996, and a continuation-in-part of application No. 08/667,003, filed on Jun. 20, 1996, now Pat. No. 6,197,745, and a continuation-in-part of application No. 08/616,371, filed on Mar. 15, 1996, now Pat. No. 6,855,691, said application No. PCT/US96/14659, filed on Sep. 13, 1996, is a continuation of application No. 08/667,003, filed on Jun. 20, 1996, now Pat. No. 6,197,745, and a continuation of application No. 08/616,371, filed on Mar. 15, 1996, now Pat. No. 6,855,691, said application No. 08/667,003, filed on Jun. 20, 1996, is a continuation-in-part of application No. 08/616,371, filed on Mar. 15, 1996, now Pat. No. 6,855,691.

(60) Provisional application No. 60/003,801, filed on Sep. 15, 1995.

(51) **Int. Cl.**[7] **A61K 38/42**; C07K 14/805

(52) **U.S. Cl.** **514/6**; 514/2; 514/832; 530/385; 530/829

(58) **Field of Search** 514/2, 6, 832; 530/385, 829

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,900,719	A	2/1990	Means et al.	514/18
5,380,758	A	1/1995	Stamler et al.	514/562
5,385,937	A	1/1995	Stamler et al.	514/557
5,395,314	A *	3/1995	Klatz et al.	604/24
5,405,919	A	4/1995	Keefer et al.	525/377
5,427,797	A	6/1995	Frostell et al.	424/434
5,439,882	A *	8/1995	Feola et al.	514/6
5,480,866	A	1/1996	Bonaventura et al.	514/6
5,574,068	A	11/1996	Stamler et al.	514/562
5,583,101	A *	12/1996	Stamler et al.	514/2
5,593,876	A	1/1997	Stamler et al.	435/188
5,863,890	A	1/1999	Stamler et al.	
6,087,479	A	7/2000	Stamler et al.	530/363
6,255,277	B1	7/2001	Stamler et al.	
6,291,424	B1	9/2001	Stamler et al.	
2002/0052314	A1	5/2002	Stamler et al.	
2003/0007967	A1	1/2003	Stamler et al.	
2003/0022267	A1	1/2003	Stamler et al.	

FOREIGN PATENT DOCUMENTS

WO	WO 93/09806	5/1993
WO	WO 93/12068	6/1993
WO	WO 94/22306	10/1994
WO	WO 94/22482	10/1994
WO	WO 94/22499	10/1994
WO	WO 95/07691	3/1995
WO	WO 96/03139	2/1996
WO	WO 96/15797	5/1996
WO	WO 96/16645	6/1996
WO	WO 96/17604	6/1996
WO	WO 96/30006	10/1996
WO	WO 97/18000	5/1997
WO	WO 97/37644	10/1997

OTHER PUBLICATIONS

U.S. Appl. No. 08/123,331, filed Sep. 17, 1993, now abandoned.
U.S. Appl. No. 08/438,418, filed May 10, 1995, now US 6,255,277.
U.S. Appl. No. 08/460,465, filed Jun. 2, 1995, now US 6,087,479.
U.S. Appl. No. 09/433,550, filed Nov. 4, 1999, now US 6,174,539.
U.S. Appl. No. 09/621,610, filed Jul. 21, 2000, now US 6,471,978.
U.S. Appl. No. 09/661,190, filed Sep. 13, 2000, now US 6,352,709.
U.S. Appl. No. 07/791,668, filed Nov. 14, 1991, now abandoned.
U.S. Appl. No. 08/198,854, filed Feb. 17, 1997, now abandoned.
U.S. Appl. No. 08/287,830, filed Aug. 9, 1994, now US 5,593,876.
U.S. Appl. No. 08/437,868, filed May 9, 1995, now abandoned.
U.S. Appl. No. 08/907,217, filed Aug. 6, 1997, now US 5,863,890.
U.S. Appl. No. 09/835,038, filed Apr. 16, 2001, published as 20020052314 (cited on PTO form 1449). The status and currently pending claims of this appliction are not known to Applicant.
U.S. Appl. No. 10/216,865, filed Aug. 13, 2002, published as 20030007967 (cited on PTO form 1449). The status and currently pending claims of this application are not known to Applicant.
U.S. Appl. No. 08/281,427, filed Jul. 27, 1994, which is the priority application for WO 96/03139. Status unknown to Applicant.
U.S. Appl. No. 08/043,653, filed Apr. 6, 1993, now US 5,427,797.

(Continued)

Primary Examiner—Bennett Celsa
(74) *Attorney, Agent, or Firm*—Hamilton, Brook, Smith & Reynolds, P.C.

(57) **ABSTRACT**

Diseases which can be ameliorated by delivery of NO to tissues affected by the disease can be treated by administration of nitrosyl-heme-containing donors of NO, including nitrosylhemoglobin. Nitrosylhemoglobin can be made by the reaction of NO with hemoglobin under certain conditions in which the NO:hemoglobin ratio is critical, and is converted to SNO-Hb under physiological conditions.

6 Claims, 28 Drawing Sheets